A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 15, 2010

Primary Completion Date

September 18, 2012

Study Completion Date

September 18, 2012

Conditions
Heart Failure, Congestive
Interventions
DRUG

GSK716155

GSK716155

DRUG

Placebo

Placebo

Trial Locations (15)

7103

GSK Investigational Site, Newark

10032

GSK Investigational Site, New York

11794

GSK Investigational Site, Stony Brook

19104

GSK Investigational Site, Philadelphia

21287

GSK Investigational Site, Baltimore

31405

GSK Investigational Site, Savannah

43210

GSK Investigational Site, Columbus

48202

GSK Investigational Site, Detroit

55407

GSK Investigational Site, Minneapolis

63110

GSK Investigational Site, St Louis

70006

GSK Investigational Site, Metairie

04210

GSK Investigational Site, Auburn

CB2 0QQ

GSK Investigational Site, Cambridge

W12 0HS

GSK Investigational Site, London

OX3 9DU

GSK Investigational Site, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY